EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide By Ogkologos - December 5, 2025 35 0 Facebook Twitter Google+ Pinterest WhatsApp It is a generic and hybrid of Xtandi, which has been authorised in the EU since 2013 Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Significant PFS Benefit in Patients with HR-positive, HER2-negative MBC Who Switched... May 26, 2023 During No-Visitor Policy at Hospital, Surgeon Comforts Breast Cancer Patient Getting... April 14, 2020 Preliminary Evidence of Efficacy of an Upfront ICI-based Therapeutic Strategy in... August 20, 2024 Mom’s Topless Photo Is Supposed To Encourage Breastfeeding, But Some Think... March 19, 2019 Load more HOT NEWS Today is Giving Tuesday One year on: How has COVID-19 affected cancer services? Elucidating a Risk of Developing Second Primary Malignancy During and After... FDA Grants Accelerated Approval to Mirvetuximab Soravtansine-gynx for FRα-Positive, Platinum-Resistant Epithelial...
